RESUMEN
AIM: To assess the efficacy, safety and tolerability of beloranib treatment for obesity. METHODS: This phase II, double-blind, randomized study investigated the effects of beloranib suspension (0.6, 1.2 and 2.4 mg) or placebo, administered subcutaneously, for 12 weeks in 147 participants (primarily white women) with obesity. No diet or exercise advice was administered. RESULTS: At week 12, beloranib resulted in dose-dependent progressive weight loss of -5.5 ± 0.5, -6.9 ± 0.6 and -10.9 ± 1.1 kg for the 0.6, 1.2 and 2.4 mg beloranib doses, respectively, compared with -0.4 ± 0.4 kg with placebo (all p < 0.0001 vs placebo). Weight loss with beloranib was associated with corresponding reductions in waist circumference and body fat mass, as well as improvements in lipids, high-sensitivity C-reactive protein and blood pressure. Sleep disturbance and gastrointestinal adverse events were more common with beloranib than with placebo; these were generally mild to moderate, transient and dose-related, and led to more early study withdrawals in participants in the group with the highest dose of beloranib. CONCLUSIONS: In this 12-week phase II study, beloranib produced clinically and statistically significant weight loss and corresponding improvements in cardiometabolic risk factors. Beloranib appeared safe, and the 0.6 and 1.2 mg doses were generally well tolerated. The 2.4 mg dose was associated with increased sleep latency and mild to moderate gastrointestinal adverse events over the first month of treatment. These findings represent a novel mechanism for producing clinically meaningful weight loss.
Asunto(s)
Aminopeptidasas/antagonistas & inhibidores , Fármacos Antiobesidad/uso terapéutico , Cinamatos/uso terapéutico , Ciclohexanos/uso terapéutico , Compuestos Epoxi/uso terapéutico , Metaloendopeptidasas/antagonistas & inhibidores , Obesidad/tratamiento farmacológico , Sesquiterpenos/uso terapéutico , Pérdida de Peso/efectos de los fármacos , Adolescente , Adulto , Anciano , Presión Sanguínea/efectos de los fármacos , Índice de Masa Corporal , Proteína C-Reactiva/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Disomnias/inducido químicamente , Femenino , Enfermedades Gastrointestinales/inducido químicamente , Humanos , Lípidos/sangre , Masculino , Persona de Mediana Edad , Obesidad/sangre , Factores de Riesgo , Circunferencia de la Cintura , Adulto JovenRESUMEN
OBJECTIVE: Evaluate the safety and tolerability of beloranib, a fumagillin-class methionine aminopetidase-2 (MetAP2) inhibitor, in obese women over 4 weeks. DESIGN AND METHODS: Thirty-one obese (mean BMI 38 kg/m2) women were randomized to intravenous 0.1, 0.3, or 0.9 mg/m2 beloranib or placebo twice weekly for 4 weeks (N = 7, 6, 9, and 9). RESULTS: The most frequent AEs were headache, infusion site injury, nausea, and diarrhea. Nausea and infusion site injury occurred more with beloranib than placebo. The most common reason for discontinuation was loss of venous access. There were no clinically significant abnormal laboratory findings. In subjects completing 4 weeks, median weight loss with 0.9 mg/m2 beloranib was -3.8 kg (95% CI -5.1, -0.9; N = 8) versus -0.6 kg with placebo (-4.5, -0.1; N = 6). Weight change for 0.1 and 0.3 mg/m2 beloranib was similar to placebo. Beloranib (0.9 mg/m2) was associated with a significant 42 and 18% reduction in triglycerides and LDL-cholesterol, as well as improvement in C-reactive protein and reduced sense of hunger. Changes in ß-hydroxybutyrate, adiponectin, leptin, and fibroblast growth factor-21 were consistent with the putative mechanism of MetAP2 inhibition. Glucose and blood pressure were unchanged. CONCLUSIONS: Beloranib treatment was well tolerated and associated with rapid weight loss and improvements in lipids, C-reactive protein, and adiponectin.
Asunto(s)
Adiponectina/sangre , Aminopeptidasas/antagonistas & inhibidores , Fármacos Antiobesidad/uso terapéutico , Ciclohexanos/uso terapéutico , Ácidos Grasos Insaturados/uso terapéutico , Glicoproteínas/antagonistas & inhibidores , Lípidos/sangre , Obesidad/tratamiento farmacológico , Pérdida de Peso/efectos de los fármacos , Ácido 3-Hidroxibutírico/sangre , Fármacos Antiobesidad/efectos adversos , Fármacos Antiobesidad/farmacología , Aspergillus/química , Productos Biológicos/efectos adversos , Productos Biológicos/farmacología , Productos Biológicos/uso terapéutico , Glucemia/metabolismo , Presión Sanguínea , Proteína C-Reactiva/metabolismo , LDL-Colesterol/sangre , Ciclohexanos/efectos adversos , Ciclohexanos/farmacología , Método Doble Ciego , Ácidos Grasos Insaturados/efectos adversos , Ácidos Grasos Insaturados/farmacología , Femenino , Factores de Crecimiento de Fibroblastos/sangre , Humanos , Hambre/efectos de los fármacos , Infusiones Intravenosas , Leptina/sangre , Metionil Aminopeptidasas , Persona de Mediana Edad , Obesidad/sangre , Sesquiterpenos/efectos adversos , Sesquiterpenos/farmacología , Sesquiterpenos/uso terapéutico , Triglicéridos/sangreRESUMEN
Peptide sequencing via tandem mass spectrometry (MS/MS) is one of the most powerful tools in proteomics for identifying proteins. Because complete genome sequences are accumulating rapidly, the recent trend in interpretation of MS/MS spectra has been database search. However, de novo MS/MS spectral interpretation remains an open problem typically involving manual interpretation by expert mass spectrometrists. We have developed a new algorithm, SHERENGA, for de novo interpretation that automatically learns fragment ion types and intensity thresholds from a collection of test spectra generated from any type of mass spectrometer. The test data are used to construct optimal path scoring in the graph representations of MS/MS spectra. A ranked list of high scoring paths corresponds to potential peptide sequences. SHERENGA is most useful for interpreting sequences of peptides resulting from unknown proteins and for validating the results of database search algorithms in fully automated, high-throughput peptide sequencing.
Asunto(s)
Algoritmos , Espectrometría de Masas/métodos , Péptidos/química , Análisis de Secuencia/métodos , Secuencia de Aminoácidos , Bases de Datos Factuales , Estudios de Evaluación como Asunto , Espectrometría de Masas/estadística & datos numéricos , Análisis de Secuencia/estadística & datos numéricosRESUMEN
Matrix-assisted laser desorption-ionization (MALDI)-postsource decay (PSD) was used to differentiate glycoprotein-released N-linked oligosaccharide isomers directly from aliquots of glycosidase digests and peak fractions collected from high-pH anion exchange chromatography (HPAEC) with minimal sample handling and material. With the implementation of instrumental tuning and acquisition controls, MALDI-PSD of NMR-characterized high-mannose, hybrid, and complex standards resulted in spectra with reproducible fragment ion peak intensity ratios which correlated well to the respective oligosaccharide branching patterns. A "knowledge-based" strategy was utilized to characterize unknown isomeric N-glycan structures in which specific fragment ion types and their distributions in the unknown PSD spectrum were compared to those in PSD spectra of standards possessing similar structural features. This PSD knowledge-based isomeric differentiation strategy was applied to distinguishing recombinant glycoprotein-derived Man7 D1 versus D2/D3 isomers directly from a PNGaseF digest aliquot of high-mannose N-glycans based on branching differences. A precursor ion selection device was employed to isolate the component of interest from the mass profile without additional chromatographic isolation steps. MALDI-MS signal-to-background was maximized for direct PSD with on-the-probe sample clean-up methods. The asialo complex N-glycan PSD knowledge base was used to differentiate HPAEC peak fractions containing the tri- and tri'-antennary branching isomers and two tetraantennary isomers with antennal versus core fucose locations. Although the particular asialo complex N-glycan isomers here were well separated by HPAEC, MALDI-MS alerted us to their presence using m/z-derived monosaccharide compositions and PSD fragmentation allowed us to differentiate these structures using the HPAEC elution positions as guides.
Asunto(s)
Oligosacáridos/química , Asparagina/química , Secuencia de Carbohidratos , Cromatografía por Intercambio Iónico , Fucosa/química , Glicoproteínas/química , Isomerismo , Manosa/química , Datos de Secuencia Molecular , Oligosacáridos/aislamiento & purificación , Polisacáridos/química , Espectrometría de Masa por Láser de Matriz Asistida de Ionización DesorciónRESUMEN
A comparative method for the quantitative analysis of the ratio of oxonium fragment (reporter) ions derived from sialic acid and N-acetylhexosamine residues on a large intact glycoprotein, the B domain of recombinant human factor VIII (rhFVIII), was developed. The method utilized liquid chromatography-electrospray ionization mass spectrometry (LC-ESI MS) on a single-quadrupole instrument. During development, systematic approaches such as full-matrix and simplex strategies were used for the optimization of the signal-to-noise ratio by controlling source temperature and cone voltage. The method was found to be precise (RSD = 0.84%), sensitive (capable of differentiating 1 sialic acid residue change among at least 29 sialic acids on a 103-kDa glycoprotein that is 38% carbohydrate), applicable to a wide range of loading (11.6-372 micrograms of FVIII), and accurate according to a comparison to matrix-assisted laser desorption-ionization time-of-flight mass spectrometry. Combining the method with enzymatic removal of N-glycans, selective O-glycan analysis was also performed leading to differential fragment ion analysis ascribed to N- and O-glycans. Quantitative ESI in-source dissociation MS combined with LC can generally be used for glycoproteins, as one of the indicators, to compare the distribution of carbohydrate residues over N- and O-glycans, to investigate their isoforms, and compare batch-to-batch characteristics of biopharmaceuticals.
Asunto(s)
Factor VIII/química , Glicoproteínas/química , Espectrometría de Masas/métodos , Amidohidrolasas/metabolismo , Conformación de Carbohidratos , Cromatografía Líquida de Alta Presión/métodos , Factor VIII/metabolismo , Glicoproteínas/metabolismo , Humanos , Fragmentos de Péptidos/química , Péptido-N4-(N-acetil-beta-glucosaminil) Asparagina Amidasa , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción/métodos , Trombina/metabolismoAsunto(s)
Electroforesis Capilar/métodos , Glicoproteínas/análisis , Manosa/análisis , Espectrometría de Masas/métodos , Factor de Crecimiento Transformador beta , Secuencia de Aminoácidos , Proteína Morfogenética Ósea 2 , Proteínas Morfogenéticas Óseas/análisis , Proteínas Morfogenéticas Óseas/química , Cromatografía por Intercambio Iónico , Glicoproteínas/química , Humanos , Conformación Molecular , Datos de Secuencia Molecular , Peso Molecular , Proteínas Recombinantes/análisis , Proteínas Recombinantes/química , Ribonucleasas/análisis , Ribonucleasas/química , Procesamiento de Señales Asistido por ComputadorRESUMEN
On-the-probe sample cleanup strategies were developed for matrix-assisted laser desorption-ionization (MALDI) time-of-flight mass spectrometry to improve the mass spectral characteristics of glycoprotein-released carbohydrate samples, including those fractionated by high pH anion exchange (HPAE) chromatography or treated with glycosidases. Small in situ amounts of chromatographic media are codeposited with matrix onto a probe containing a carbohydrate sample to minimize interferences from cations, anions, and/or detergents introduced from the sample and/or matrix. On-the-probe sample cleanup is fast (a few minutes) and operates best on picomole quantities of analyte in sample volumes less than 5 microliter containing nanomole quantities or less of impurities. This in situ cleanup dramatically increases the mass spectral signal-to-background, improves mass accuracies, better equalizes the sensitivities for diverse carbohydrate structures, and has the potential to remove contaminants that bypassed previous purification schemes. Direct MALDI mass profiling of digest aliquots containing low picomole amounts of carbohydrate structures either enzymatically released from a glycoprotein or sequentially degraded with multiple glycosidases was performed using only microscale digest conditions with reduced buffer amounts and on-the-probe sample cleanup to minimize the digest impurities. Membrane microdialysis was compared to on-the-probe sample cleanup and found to more completely remove the nano- to micromole amounts of anions (and cations) in HPAE fractions in one step as opposed to multiple on-the-probe steps.
Asunto(s)
Carbohidratos/química , Glicoproteínas/química , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción/métodos , Conformación de Carbohidratos , Fraccionamiento Químico , Cromatografía por Intercambio Iónico , Detergentes , Glicósido Hidrolasas , Microdiálisis , Neuraminidasa , Proteínas Recombinantes/químicaRESUMEN
Abundant ions corresponding to the gas-phase cleavage of the Asp-Pro and Asp-Xxx bonds of peptides in the process of matrix-assisted laser desorption were observed using a time-of-flight mass spectrometer equipped with both linear and reflector mass analyzers. Peptides containing the N-terminal sequence, Asp-Pro ... from an endoproteinase Asp-N digest yielded one peak in the molecular ion region in the linear mode and two equally abundant peaks in the reflector mode TOF mass spectra. The lower molecular masses in the reflector mode mass spectra could be eliminated by removing the Asp residue or derivatizing its side-chain carboxyl group. The observed mass differences did not correspond to any amino acid; however, by lowering the potential of the reflector to correct for the energy loss the mass difference was determined to be 115 Da, i.e., Asp. The extent and rate of this decomposition was compared with that obtained using a four-sector tandem mass spectrometer in the MS/MS mode of operation without and with a collision gas at collision cell potentials of 3.0 and 9.86 kV. These data suggest the Asp-Pro peptide bond is more labile than other peptide bonds in the gas phase. Abundant metastable decomposition of internal Asp-Pro bonds was also observed in larger peptides and proteins. Based on these latter data, a mechanism for this gas-phase cleavage is proposed.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Espectrometría de Masas/métodos , Fragmentos de Péptidos/química , Secuencia de Aminoácidos , Ácido Aspártico/química , Escherichia coli/química , Hidrólisis , Rayos Láser , Datos de Secuencia Molecular , Prolina/química , Tiorredoxinas/químicaRESUMEN
The utility of matrix-assisted laser desorption time-of-flight (MALD-TOF) mass spectrometry for the analysis of recombinant glycopeptides is discussed and compared to information which may be obtained by fast atom bombardment mass spectrometry (FABMS) and tandem mass spectrometry (MS/MS). MALD-TOF appears to be 10-100 times more sensitive than FAB MS for the analysis of underivatized glycopeptides, providing qualitative site-specific information regarding the carbohydrate microheterogeneity without the extensive isolation and derivatization procedures required to obtain similar information by FAB MS. Analysis of a digest mixture in the positive and negative ion mode of MALD-TOF indicated that, in mixtures, sialylated glycopeptides are preferentially detected in the negative ion mode. The determination of the molecular masses of a glycopeptide with MALD-TOF prior to and after treatment with a variety of specific glycosidases, often without removal of the buffers, coupled to a comparison of molecular mass information available from a carbohydrate database facilitates the assignment of a carbohydrate composition. The vast majority of the molecular ion signal observed in the linear mode for sialylated glycopeptides are metastable ions. Reflector mass spectra reveal a shift to lower mass consistent with the loss of most of the neuraminic acid residues. The loss of Hex and HexNAc residues is also observed. Sequential lowering of the reflector potential reveals structurally significant fragment ions representing the carbohydrate and peptide portions of the molecule.
Asunto(s)
Carbohidratos/análisis , Espectrometría de Masas/métodos , Proteínas Recombinantes/química , Secuencia de Aminoácidos , Secuencia de Carbohidratos , Glicoproteínas/química , Glicósido Hidrolasas , Humanos , Factor Estimulante de Colonias de Macrófagos/química , Datos de Secuencia Molecular , Peso MolecularAsunto(s)
Glucolípidos/química , Secuencia de Carbohidratos , Cromatografía de Gases y Espectrometría de Masas/métodos , Espectrometría de Masas/métodos , Datos de Secuencia Molecular , Espectrometría de Masa Bombardeada por Átomos Veloces/instrumentación , Espectrometría de Masa Bombardeada por Átomos Veloces/métodos , Terminología como AsuntoRESUMEN
Microscale reduction of ceramides and neutral glycosphingolipids has been evaluated as a means of improving their analysis by fast atom bombardment mass spectrometry, alone and in combination with tandem mass spectrometry. Reduction (conversion of the amide to an amine) of native ceramides and glycosphingolipids containing one to three sugars yields derivatives that show significant signal enhancement. This sensitivity increase allows the acquisition of normal and tandem fast atom bombardment mass spectra from a submicrogram amount of sample. Concomitant permethylation is required for glycosphingolipids that contain more than three sugars. Collision induced dissociation mass spectra of protonated molecular ions, recorded on a four sector instrument, show improved fragmentation allowing the simultaneous characterization of both the ceramide and carbohydrate portions of glycosphingolipids. The reductions are carried out at the nanogram to microgram level with borane, reacting the solid sample with condensed reagent vapor. The borane reduction method has been adapted for this class of substances by adding an oxidation step in order to convert unsaturated lipids to hydroxylated derivatives by oxidation of the resulting organoborane. This approach, used in conjunction with tandem mass spectrometry, allows the determination of olefinic bond location. Labeled derivatives have been prepared by reacting the substrates with trideuterioborane and were used to ascertain the fragmentations and localize olefinic bonds. The collision induced fragmentation of reduced ceramides and neutral glycosphingolipids is only weakly affected by the presence of additional functionalities, such as methoxyl (after permethylation) and hydroxyl groups (resulting from hydroboration and oxidation), a characteristic which facilitates interpretation of the spectra of unknown compounds.
Asunto(s)
Ceramidas/análisis , Glicoesfingolípidos/análisis , Animales , Galactosilceramidas/análisis , Espectrometría de Masas/métodos , Metilación , Microquímica/métodos , Oxidación-Reducción , SpirometraRESUMEN
A glutaredoxin was purified from rabbit bone marrow, and its amino acid sequence was determined by high performance tandem mass spectrometry. The sequences of peptides generated by digestion with trypsin alone or in combination with thermolysin were determined from their collision-induced dissociation (CID) mass spectra. Alignment of these sequences and additional sequence information were obtained from the collision-induced dissociation mass spectra of peptides obtained from digestion of the intact protein with Staphylococcus aureus V8 protease and alpha-chymotrypsin. The resulting sequence of 106 amino acids is as follows: Ac-Ala-Gln-Glu-Phe-Val-Asn-Ser-Lys-Ile-Gln-Pro-Gly-Lys-Val-Val-Val-Phe- Ile-Lys-Pro-Thr-Cys-Pro-Tyr-Cys-Arg-Lys-Thr-Gln-Glu-Ile-Leu-Ser-Glu-Leu- Pro-Phe - Lys-Gln-Gly-Leu-Leu-Glu-Phe- Val-Asp-Ile-Thr-Ala-Thr-Ser-Asp-Met-Ser-Glu-Ile- Gln-Asp-Tyr-Leu-Gln-Gln-Leu-Thr-Gly-Ala-Arg- Thr-Val-Pro-Arg-Val-Phe-Leu-Gly-Lys-Asp-Cys-Ile- Gly-Gly-Cys-Ser-Asp-Leu-Ile-Ala-Met-Gln-Glu-Lys- Gly-Glu-Leu-Leu-Ala-Arg-Leu-Lys-Glu-Met-Gly- Ala-Leu-Arg-Gln. This glutaredoxin strongly resembles the corresponding calf and pig proteins (known as glutaredoxin and thioltransferase, respectively) with respect to its primary structure and enzymatic activity as a GSH:disulfide thioltransferase, an activity also found for the glutaredoxin from Escherichia coli. However, rabbit glutaredoxin was not active as a hydrogen donor for the reduction of ribonucleotides in the presence of the ribonucleotide reductases from rabbit bone marrow, Lactobacillus leichmannii, and Corynebacterium nephridii.